| Literature DB >> 34006891 |
Meyke Hermsen1, Valery Volk2, Jan Hinrich Bräsen2, Daan J Geijs1, Wilfried Gwinner3, Jesper Kers4,5,6, Jasper Linmans1, Nadine S Schaadt7, Jessica Schmitz2, Eric J Steenbergen1, Zaneta Swiderska-Chadaj1,8, Bart Smeets1, Luuk B Hilbrands9, Friedrich Feuerhake2,10, Jeroen A W M van der Laak11,12.
Abstract
Delayed graft function (DGF) is a strong risk factor for development of interstitial fibrosis and tubular atrophy (IFTA) in kidney transplants. Quantitative assessment of inflammatory infiltrates in kidney biopsies of DGF patients can reveal predictive markers for IFTA development. In this study, we combined multiplex tyramide signal amplification (mTSA) and convolutional neural networks (CNNs) to assess the inflammatory microenvironment in kidney biopsies of DGF patients (n = 22) taken at 6 weeks post-transplantation. Patients were stratified for IFTA development (<10% versus ≥10%) from 6 weeks to 6 months post-transplantation, based on histopathological assessment by three kidney pathologists. One mTSA panel was developed for visualization of capillaries, T- and B-lymphocytes and macrophages and a second mTSA panel for T-helper cell and macrophage subsets. The slides were multi spectrally imaged and custom-made python scripts enabled conversion to artificial brightfield whole-slide images (WSI). We used an existing CNN for the detection of lymphocytes with cytoplasmatic staining patterns in immunohistochemistry and developed two new CNNs for the detection of macrophages and nuclear-stained lymphocytes. F1-scores were 0.77 (nuclear-stained lymphocytes), 0.81 (cytoplasmatic-stained lymphocytes), and 0.82 (macrophages) on a test set of artificial brightfield WSI. The CNNs were used to detect inflammatory cells, after which we assessed the peritubular capillary extent, cell density, cell ratios, and cell distance in the two patient groups. In this cohort, distance of macrophages to other immune cells and peritubular capillary extent did not vary significantly at 6 weeks post-transplantation between patient groups. CD163+ cell density was higher in patients with ≥10% IFTA development 6 months post-transplantation (p < 0.05). CD3+CD8-/CD3+CD8+ ratios were higher in patients with <10% IFTA development (p < 0.05). We observed a high correlation between CD163+ and CD4+GATA3+ cell density (R = 0.74, p < 0.001). Our study demonstrates that CNNs can be used to leverage reliable, quantitative results from mTSA-stained, multi spectrally imaged slides of kidney transplant biopsies.Entities:
Mesh:
Year: 2021 PMID: 34006891 PMCID: PMC8292146 DOI: 10.1038/s41374-021-00601-w
Source DB: PubMed Journal: Lab Invest ISSN: 0023-6837 Impact factor: 5.502
Patient and donor characteristics categorized by the IFTA development (<10% or ≥10%) from 6 weeks to 6 months post-transplantation.
| ΔIFTA < 10% ( | ΔIFTA ≥ 10% ( | |
|---|---|---|
| Recipient | ||
| Female (%) | 3 (33.3) | 7 (53.8) |
| Age, yr | 54.4 (36.7–66.0) | 56.8 (32.8–69.3) |
| BMI, kg/m2 | 27.5 (22.7–31.0) | 27.9 (22.2–30.4) |
| Dialysis time, months | 79.4 (7.5–109.3) | 57.8 (17.5–196.6) |
| Pre-formed panel reactive antibodies, % | 0 (0–0) | 0 (0–85) |
| Number of transplants | 1 (1–1) | 1 (1–3) |
| Underlying renal disease | ||
| Glomerulonephritis/vasculitis | 1 (11.1) | 3 (23.1) |
| Tubulo-interstitial disease | 1 (11.1) | 1 (7.7) |
| Hypertensive/diabetic nephropathy | 1 (11.1) | 3 (23.1) |
| Congenital disease | 1 (11.1) | 1 (7.7) |
| Other specified disease | 0 (0) | 1 (7.7) |
| Unknown | 5 (55.6) | 4 (30.8) |
| Graft characteristics | ||
| Age donor | 50 (38–63) | 49 (27–75) |
| HLA-A mismatch | 0 (0–1) | 1 (0–2) |
| HLA-B mismatch | 1 (0–2) | 0 (0–2) |
| HLA-DR mismatch | 0 (0–1) | 1 (0–1) |
| Deceased donor | 8 (88.9) | 13 (100) |
| Cold ischemia time, hours | 14.2 (2.3–22.3) | 15.5 (11.6–27.4) |
| Induction therapy* | ||
| None | 2 (22.2) | 0 (0) |
| Anti-IL-2 antibodies | 5 (55.6) | 10 (76.9) |
| Anti-thymocyte globulin | 0 (0) | 3 (23.1) |
| Alemtuzumab | 2 (22.2) | 0 (0) |
| Plasmapheresis | 0 (0) | 2 (15.4) |
| Maintenance therapy | ||
| Cyclosporin | 3 (33.3) | 9 (69.2) |
| Tacrolimus | 5 (55.6) | 4 (30.8) |
| Mycophenolate mofetil/mycophenolic acid | 3 (33.3) | 9 (69.2) |
| Azathioprine | 0 (0) | 0 (0) |
| Rapamycine | 0 (0) | 0 (0) |
| Belatacept | 1 (11.1) | 0 (0) |
| Sotrastaurin | 1 (11.1) | 0 (0) |
| Steroids | 7 (77.8) | 12 (92.3) |
| Clinical events < 6 months post-transplantation | ||
| Hydronephrosis | 2 (22.2) | 5 (38.5) |
| BKV nephritis | 0 (0) | 0 (0) |
| Urinary tract infection | 0 (0) | 4 (30.8) |
| Sepsis or other severe infection | 0 (0) | 0 (0) |
| Graft function | ||
| Serum creatinine, µmol/l | 178.0 (101–293) | 157.0 (116–383) |
| Serum creatinine, µmol/l at 6 months | 146.0 (107–364) | 154 (98–860) |
| Proteinuria, g/l | 0.0 (0.0–0.08) | 0.0 (0.0–0.15) |
| Proteinuria, g/l at 6-months | 0.0 (0.0–0.07) | 0.0 (0.0–0.08) |
| eGFR (CKD-EPI), ml/min/1.73 m2 | 36.0 (15–55) | 35.0 (14–47) |
| eGFR (CKD-EPI), ml/min/1.73 m2 at 6-months | 44.0 (11–58) | 33.0 (5–79) |
| Banff lesion scores | ||
| Total inflammation (ti) | 1 (0–2) | 1 (0–1) |
| Inflammation in non-scarred parenchyma (i) | 0 (0–1) | 0 (0–1) |
| Inflammation in scarred parenchyma (i-IFTA) | 2 (0–3) | 2 (0–3) |
| Interstitial fibrosis (ci) | 0 (0–1) | 0 (0–1) |
| Tubular atrophy (ct) | 0 (0–1) | 1 (0–1) |
| Banff lesion scores at 6 months | ||
| Total inflammation (ti) | 1 (0–2) | 1 (0–3) |
| Inflammation in non-scarred parenchyma (i) | 0 (0–1) | 0 (0–3) |
| Inflammation in scarred parenchyma (i-IFTA)* | 1 (0–3) | 3 (1–3) |
| Interstitial fibrosis (ci) | 0 (0–1) | 1 (0–2) |
| Tubular atrophy (ct) | 1 (0–1) | 1 (0–2) |
| IFTA percentages | ||
| IFTA 6 weeks | 9.7 (0–30) | 7.5 (0.17–22.5) |
| IFTA 6 months** | 5.0 (1.67–33.33) | 25.0 (12.5–68.3) |
| ΔIFTA 6 weeks to 6-months** | 1.0 (−12.5–5.0) | 19.0 (11.5–61.7) |
The median (minimum–maximum value) or occurrences (percentages or minimum–maximum value) are reported.
BMI body mass index, HLA human leukocyte antigen, Il-2 interleukin 2, BKV BK virus, eGFR estimated glomerular filtration rate.
*p < 0.05; **p < 0.001.
Fig. 1Conversion of an mTSA-stained slide to an artificial brightfield IHC WSI.
The mTSA slide was multi spectrally imaged on the Vectra system, resulting in multispectral tiles (1). The tiles were unmixed by the Inform software, leading to multi-channeled tiles where each channel represents one marker (2). The tiles were subsequently stitched into a multi-channeled WSI (3). In this example, the channels representing DAPI and CD4 were selected be combined in one WSI (4). Stain vectors acquired in previous studies were used to artificially color the DAPI signal blue (hematoxylin) and the CD4 signal brown (DAB), resulting in an artificial brightfield IHC WSI (5).
Fig. 2Regions from two mTSA-stained slides, displaying the multiplex IHC and the artificial brightfield representation for every antibody.
First and third row: multiplex IHC (left) and artificial brightfield images for every antibody (brown) combined with DAPI (blue). Second and bottom row: cell detections performed by the CNNs (lymphocytes and macrophages, filled circles) and segmented regions through image processing (capillaries, CD34, filled shapes).
Performance of the CNNs that were used for quantitative assessment of inflammatory infiltrates in this study.
| Traditional IHC WSI | Artificial brightfield IHC WSI | |||||
|---|---|---|---|---|---|---|
| Precision | Recall | F1 | Precision | Recall | F1 | |
| Lymphocyte detection CNN I [ | 0.76a | 0.79a | 0.78a | 0.92 | 0.73 | 0.81 |
| Lymphocyte detection CNN II | 0.81 | 0.88 | 0.84 | 0.71 | 0.84 | 0.77 |
| Macrophage detection CNN | 0.79 | 0.75 | 0.77 | 0.93 | 0.74 | 0.82 |
aData from original research paper [22].
Fig. 3Using distance of cell detections to include CD4+GATA3+ cells and exclude GATA3+ epithelial cells from the analysis.
Column A: artificial IHC representing CD4 without (top) and with (bottom) cell detections. The epithelial cells (red circle) are negative for CD4. Column B: artificial IHC representing GATA3 without (top) and with (bottom) cell detections. The epithelial cells (red circle) are positive for GATA3 and detected by the neural network. Column C: artificial IHC representing GATA3 without (top) and with (bottom) cell detections closer than eight pixels to a CD4 cell detection. The epithelial cells (red circle) are removed from the cell detections.
Median CD34+ pixel percentages, cell densities cells/mm2 (min–max) and mean cell ratios (standard deviation) in the cortical tubulointerstitium of the 6 weeks biopsies, excluding the subcortical region.
| ΔIFTA < 10% ( | ΔIFTA ≥ 10% ( | ||
|---|---|---|---|
| Panel I | |||
| CD34+ | 7.77 (6.30–12.35) | 8.17 (6.62–11.07) | 0.74 |
| CD3+ | 413 (90–861) | 303 (93–905) | 0.65 |
| CD3+CD4+ | 70 (8–186) | 39 (2–300) | 0.56 |
| CD3+CD8+ | 23 (7–235) | 32 (8–268) | 0.19 |
| CD3+CD8− | 296 (79–821) | 221 (81–827) | 0.70 |
| CD20+ | 6 (0–59) | 8 (2–211) | 0.21 |
| CD68+ | 203 (90–532) | 328 (142–578) | 0.07 |
| Panel II | |||
| CD4+ | 88 (13–680) | 197 (27–1215) | 0.39 |
| CD4+Tbet+ | 3 (0–58) | 6 (0–102) | 0.29 |
| CD4+GATA3+ | 11 (0–241) | 51 (1–249) | 0.24 |
| CD68+ | 92 (8–459) | 72 (27–351) | 0.90 |
| CD163+ | 370 (105–625) | 505 (112–781) | 0.04 |
| CD68+CD163+ | 74 (8–368) | 64 (24–315) | 1 |
| Cell ratios | |||
| CD3+CD8−/CD3+CD8+ | 17.47 (9.05) | 9.80 (7.55) | 0.04 |
Fig. 4Mean shortest cell distances.
Boxplots representing the mean shortest distance (measured in pixels (px)) from CD68+ cells (panel I) and CD163+ cells (panel II) to other immune cells, based on analyses excluding the subcapsular region, according to ∆IFTA percentages 6 weeks and 6 months post-transplantation.